Clinical trials: Osteoporosis Postmenopausal
Postmenopausal Osteoporosis
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
The primary objective of the study was to evaluate the effect of 12 months of treatment with romosozumab compared with teriparatide on total hip bone mineral density (BMD) in postmenopausal women with osteoporosis who were…
- Trial name
- STRUCTURE (NCT01796301)
- Testing
- Romozosumab, Teriparatide
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 436 people
- Sponsor
- Amgen
Osteoporosis
Risedronate in Osteopenic Postmenopausal Women
The primary objective of this study is to compare risedronate 35 mg and placebo with respect to the percent change at 12 months for distal radius trabecular bone volume (BV/TV) in osteopenic postmenopausal women, as measured by…
- Trial name
- OSMAUSE (NCT00345644)
- Testing
- risedronate
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Sanofi
Osteoporosis
Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis
This observational study assess the safety of intravenous Ibandronate (Bonviva) intermittent administration in patients with postmenopausal osteoporosis and the efficacy of IV Ibandronate (Bonviva treatment through relative…
- Trial name
- NCT02271204
- Testing
- Ibandronic acid
- Volunteers
- 700 people
- Sponsor
- Clinic of Endocrinology and Metabolic Disorders, Macedonia
Osteoporosis
Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
The aim of this study is to determine whether denosumab (an FDA-approved osteoporosis therapy), in combination with teriparatide (an FDA-approved osteoporosis therapy), will increase bone mineral density more than either one…
- Trial name
- DATA (NCT00926380)
- Testing
- denosumab, teriparatide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Massachusetts General Hospital
Osteoporosis
Safety and Tolerability of Odanacatib (0822-059)
This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib
- Trial name
- NCT01068262
- Testing
- Odanacatib
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporosis, Postmenopausal
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
The purpose of this study is to compare how well alendronate and raloxifene increase the bone density in women who have osteoporosis and have experienced menopause.
- Trial name
- NCT00389740
- Testing
- MK0217, /Duration of Treatment : 12 Months, Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months
- Volunteers
- 400 people
- Sponsor
- Organon and Co
Osteoporosis, Osteoporosis, Postmenopausal
Association of Cystatin C and Bone Mineral Density in Diabetic Patients.
Type 1 diabetes is associated with low bone mineral density(BMD) and type 2 diabetes with normal or high BMD. Cystatin C is a small molecule that is used to measure kidney function but it's not a troponin of the kidney.
- Conditions
- Osteoporosis, Osteoporosis, Postmenopausal, Diabetes Mellitus
- Trial name
- NCT04019938
- Testing
- Dual-energy X-ray absorptiometry
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Osteoporosis, Osteopenia
Serum Myostatin and Irisin Levels in Postmenopausal Women: Association With Bone Mineral Density and Muscle Strength
This study aims to evaluate the relationship between serum myostatin and irisin levels and bone mineral density and muscle strength in postmenopausal women.
- Trial name
- MYOIRISIN (NCT07519551)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Osteoporosis
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A double-blind, placebo-controlled, parallel-group study to assess the safety and efficacy of 3 doses of ALX1-11 (recombinant human parathyroid hormone [rhPTH(1-84)])(50, 75 and 100 µg) in the treatment of postmenopausal…
- Trial name
- NCT00172107
- Testing
- ALX1-11 50 mcg, ALX1-11 75mcg, ALX1-11
- Where
- 19 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- Shire
Osteoporosis
Open Label Extension Study of PREOS
This is an Open Label Extension Study (OLES) for patients who participated in the 18 month double-blind, placebo-controlled, Phase III trial (Protocol ALX1 11 93001 the TOP Study) studying the effect of ALX1-11, recombinant human…
- Trial name
- OLES (NCT00172133)
- Testing
- ALX1-11 (drug)
- Where
- 132 sites in United States, Argentina and 6 more
- Volunteers
- 1,683 people
- Sponsor
- Shire
Osteoporosis Fracture
Evaluating Fracture Risk Assessment Tools (FRAX) From Different Regions in Central South Chinese Postmenopausal Women
We evaluated fracture risk assessment tools (FRAXs) from different regions in Chinese postmenopausal women.
- Trial name
- NCT04960033
- Testing
- FRAX
- Where
- China
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Central South University
Osteoporosis
A Dose Selection Study of Oral Recombinant Salmon Calcitonin (rsCT) in Normal, Healthy, Postmenopausal Women
This study compares the performance of different doses of oral recombinant salmon calcitonin (rsCT).
- Trial name
- NCT00620854
- Testing
- Recombinant Salmon Calcitonin (rsCT), Oral Tablet, Nasal Spray
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tarsa Therapeutics, Inc.
Osteoporosis, Postmenopausal
FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051)
This study was conducted among women who had previously received alendronate for 3 to 6 years during the Fracture Intervention Trial (FIT).
- Trial name
- NCT00398931
- Testing
- MK0217, alendronate sodium / Duration of Treatment : 5 Years
- Volunteers
- 1,099 people
- Sponsor
- Organon and Co
Kidney Yang Deficiency Syndrome
The Study of LTBP1 of Postmenopausal Women Osteoporosis Molecular Mechanism of Kidney Yang Deficiency Syndrome
Postmenopausal Osteoporosis is characterized by a decrease in bone mass as well as a deterioration of the bone architecture resulting in an increased risk of fracture,which is directly related to the lack of estrogen and also…
- Trial name
- NCT01940380
- Where
- China
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Fujian Academy of Traditional Chinese Medicine
Post-menopausal Osteoporosis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women
This study is designed to provide information about the bone-anabolic response of PTH134 when administered orally, in comparison to Forsteo®, the sub-cutaneous form of teriparatide, the active ingredient in PTH134.
- Trial name
- NCT01224717
- Testing
- PTH134, Forsteo
- Where
- 4 sites in Denmark, Germany
- Volunteers
- 104 people
- Sponsor
- Novartis
Postmenopausal Osteoporosis, Gut Microbiome
Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females
The goal of this clinical trial is to evaluate the effects of blackcurrant (BC) supplementation on changes in bone density and gut microbiome composition in postmenopausal females.
- Conditions
- Postmenopausal Osteoporosis, Gut Microbiome, Menopause
- Trial name
- NCT07365514
- Testing
- Blackcurrant (BC) extract
- Where
- United States
- Volunteers
- 159 people, healthy volunteers welcome
- Sponsor
- University of Connecticut
Osteoporosis, Postmenopausal
Menopause Osteoporosis and Bone Intervention Using Lifestyle Exercise.
Aim: to examine the effect of an exercise intervention for preventing osteoporosis among postmenopausal women. Objectives: To examine whether mean values for Broadband Ultrasound Attenuation (BUA) using Quantitative Ultrasound…
- Trial name
- MOBILE (NCT04469374)
- Testing
- Jumping exercise
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Staffordshire University
Postmenopausal Osteoporosis, Agility Exercise
Compare the Agility Exercise and Resistance Exercise on Physical Function and Stability in Osteoporotic Women
Osteoporosis weakens bones with age, increasing fracture risk. Exercise improves physical function and reduces falls, crucial for preventing osteoporotic fractures, especially with balance, resistance, and multi-component…
- Conditions
- Postmenopausal Osteoporosis, Agility Exercise, Physical Function, Balance Stability
- Trial name
- NCT06457308
- Testing
- Physical training of agility, Physical training of resistance
- Where
- Taiwan
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Tainan Hospital, Ministry of Health and Welfare
Postural Balance
Evaluation of the Association Between Osteoporosis and Postural Balance in Postmenopausal Women
The incidence of osteoporosis has been increasing, as have fractures resulting from falls.
- Trial name
- NCT02771834
- Testing
- Biomechanical analysis, Kiphosis analysis, Vitamin D level
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Osteoporosis, Bone Loss, Age Related
Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women
To develop a decision aid to support the decision to use (or not use) bisphosphonates in postmenopausal women at risk for osteoporotic fractures, and to assess the impact of the decision aid on start and six month adherence to…
- Conditions
- Osteoporosis, Bone Loss, Age Related, Postmenopausal Bone Loss, Postmenopausal Osteoporosis
- Trial name
- NCT00578981
- Testing
- Osteoporosis Choice Decision Aid
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic